Member Info for occams

You can't short this on IG , probably be the same on Spreadex, so must be a long bet

You are a disgusting individual

NMC Health was a FTSE 100 company

Cash in the bank £142m, market cap £141m.
This is AIM, PI's are always the last to find out what's going on,
by then it's usually too late.

From 30th April RNS,. As a result of strengthened cash control measures, the Group has been able to preserve its liquidity position and, at the close of business on Friday 24 April 2020, it held cash of £142m. The Group remains in dialogue with its lending group in order to release additional liquidity as required.
Why would they need more liquidity if they have £142m cash?

https://www.theguardian.com/world/2020/may/21/uk-coronavirus-test-with-20-minute-wait-being-trialled

Also speaking at the No 10 briefing, Prof John Newton, who is in charge of the government’s testing efforts, said quick test results were a key element. Currently, he said, 90% of results come within 48 hours, and almost half within 24 hours.

https://www.theguardian.com/world/2020/may/21/global-report-coronavirus-vaccine-us-scientist-cases-5-million

Arthur Daley's your man

https://www.theguardian.com/world/2020/may/19/china-puts-city-of-shulan-under-wuhan-style-lockdown-after-fresh-covid-19-cases

It's investors buying and selling from MM's. The red's aren't all sells , on this site anything below the mid price is written as a sell and vice versa

Commenting, Stephen Stamp, CEO and CFO said "Today's combined US and UK fundraising does not change our priority, that being to extract maximum value from Midatech's platform technologies for stakeholders. What it does do is provide us more time to deliver on some short term R&D goals and flexibility to secure long term solutions".

18 May 2020 - Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that it has entered into definitive binding agreements with institutional investors (the "Investors") for the purchase in a registered direct offering (the "Offering") of 1,818,182 of its American Depositary Shares ("ADSs") (each ADS representing five of the Company's ordinary shares (the "New Ordinary Shares")) at a purchase price of US$1.65 per ADS (equivalent to £0.27 per New Ordinary Share), for aggregate gross proceeds of US$3.0 million (£2.5 million). Additionally, in a concurrent private placement, the Company has agreed to issue to the Investors unregistered warrants to purchase up to an aggregate of 1,818,182 ADSs. The Offering is expected to close on or about May 20, 2020, subject to satisfaction of customary closing conditions.

Quoting 1p above ask even to buy £1000 worth

Established in 2001, Fusion provides a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

“Since 2012 it has sequenced and expressed over 250 antibodies and completed over 100 humanisation projects, and has an international blue-chip client base which has included eight of the top 10 global pharmaceutical companies by revenue,” the company said in a statement issued after the agm.

The global monoclonal antibody therapeutics market was valued at $135.4 billion in 2018, and is forecast to surpass $212.6 billion in 2022. In 2017 seven of the world’s 10 top-selling drugs were antibody-based therapeutics, with the combined annual sales of these drugs exceeding $63.2 billion.

A health minister has hailed the UK’s approval of an immunity test for coronavirus as a game changer that could allow more people to go to work with confidence, although the government has not yet managed to buy any of the tests.

Maybe CMS are a potential bidder , that's why they left the board

Speaking at today's daily press briefing, Patrick Vallance, the Chief Scientific Adviser said that data shows that in London, around 10 per cent of people tested positive for coronavirus antibodies from tests, showing they have had the virus.

Across the country however, he said that amount was around 4 per cent.

The UK government would like the general public to conduct their own tests through fingerprick kits made available in their millions through Amazon or Boots in the coming weeks.

However, these plans stalled last month when 4m antibody tests purchased from China at a cost of £16m were found by Oxford University scientists to have both insufficient sensitivity and specificity for mass use. Up to 17.5m more tests have now been provisionally ordered from companies across the UK.

https://www.telegraph.co.uk/global-health/science-and-disease/makers-home-antibody-test-seek-urgent-nhs-approval/

https://www.theguardian.com/society/2020/may/10/scientists-concerned-that-coronavirus-is-adapting-to-humans